Centennial, Colo. — January 19, 2016 — AlloSource®, one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, was awarded U.S. Patent Number 9,186,253, titled Cartilage mosaic compositions and methods, for its new cartilage repair allograft, ProChondrix® Cartilage Restoration Matrix.
ProChondrix is a cellular 3D fresh cartilage matrix that helps deliver the necessary components for cartilage restoration. This next generation of cartilage therapy provides live functional cells and other biological components necessary for repair and regeneration of damaged cartilage tissues.
“With thousands of cartilage repair surgeries performed in the U.S. each year, this is another opportunity for donor tissue to improve lives,” said Dr. Peter Stevens, PhD, AlloSource Vice President of Development and Growth. “The initial feedback from surgeons on ProChondrix has been positive and we look forward to continued collaboration in helping patients heal.”
By focusing on quality, safety, service and a commitment to its mission, AlloSource has grown into one of the nation’s largest tissue networks. The company’s safety and tissue processing standards meet and exceed guidelines set forth by the United States Food and Drug Administration (FDA) and the American Association of Tissue Banks (AATB).